Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102048 | 0.87 | TLR7 (0.41) | TLR7ADORA2AADORA3ADORA1NUDT1 | |
| SCHEMBL4099745 | 0.87 | TLR7 (0.40) | TLR7ADORA2AADORA3ADORA1NUDT1 | |
| SCHEMBL4095899 | 0.78 | TLR7 (0.48) | TLR7ADORA2AADORA3ADORA1NUDT1 | |
| SCHEMBL4102038 | 0.78 | TLR7 (0.42) | TLR7ADORA2AADORA3ADORA1NUDT1 | |
| SCHEMBL3996500 | 0.76 | HPRT1 (0.45) | TLR7ADORA2AADORA2B | |
| SCHEMBL4104451 | 0.76 | CYP3A4 (0.41) | TLR7 | |
| SCHEMBL14311956 | 0.75 | TLR7 (0.51) | TLR7ADORA2AADORA3ADORA1NUDT1 | |
| SCHEMBL4100830 | 0.75 | SERPINA3 (0.43) | TLR7ADORA2AADORA1NUDT1ADORA2B | |
| SCHEMBL4108240 | 0.74 | TLR7 (0.44) | TLR7ADORA2AADORA3ADORA1NUDT1 | |
| SCHEMBL3925889 | 0.74 | TLR7 (0.42) | TLR7ADORA2AADORA3ADORA1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038290-B1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | TLR7 1/4885ADORA2A 991/4885ADORA3 1929/4885 |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | TLR7 1/4885ADORA2A 917/4885ADORA3 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.